)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Fate Therapeutics
Fate Therapeutics (FATE) investor relations material
Fate Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary5 Nov, 2026
Company overview and business model
Clinical-stage biopharma platform engineers induced pluripotent stem cells (iPSCs) into clonal master lines for scalable, off-the-shelf cellular immunotherapies.
Pipeline includes iPSC-derived CAR T-cell and natural killer (NK) candidates; Ono collaboration covers CAR T-cell candidates for solid tumors.
Cellular programming adds synthetic controls and multiple functional elements to produce uniform candidates intended for use alone or with standard-of-care therapies.
Financial performance and metrics
Cash, cash equivalents and short-term investments totaled $139.1 million as of September 30, 2026.
Prior Jefferies ATM sales generated $8.0 million gross proceeds from 2,801,602 shares in Q3 2026; that sales agreement was terminated upon entering the Leerink agreement.
Use of proceeds and capital allocation
ATM net proceeds, if any, are intended for working capital and general corporate purposes, including R&D, clinical trials, manufacturing, G&A and capital expenditures.
Timing and allocation depend on clinical and development progress, partnering efforts, technology advances and competition; management retains broad discretion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Fate Therapeutics
- RECLAIM-LN advanced as management’s grant-inclusive runway outlook extended to mid-2028.FATE
Q3 2026 - Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis.FATE12th Annual Cantor Fitzgerald Global Healthcare Conference
- Net loss narrowed, cash runway into 2028, and pivotal CAR T-cell trials advanced.FATEQ2 2026
- Early lupus trial data with flexible CAR T protocols expected by year-end, focusing on B-cell reset.FATEJefferies 2024 Global Healthcare Conference
- FT819 and next-gen CAR T-cell therapies show strong clinical progress and financial stability.FATECorporate presentation
- Net loss narrowed on lower expenses, with strong cash and key CAR T-cell advances, but risks remain.FATEQ1 2026
- Key votes include director elections, auditor ratification, and incentive plan amendment.FATEProxy filing
- Shareholders will vote on director elections, auditor ratification, say-on-pay, and equity plan expansion.FATEProxy filing
- iPSC-derived CAR T therapies show promise in SLE and oncology, with pivotal trials and updates ahead.FATE25th Annual Needham Virtual Healthcare Conference
Next Fate Therapeutics earnings date
38th Annual Healthcare Conference1 Dec, 2026
Fate Therapeutics
Next Fate Therapeutics earnings date
38th Annual Healthcare Conference1 Dec, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.